<unk>  is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. It is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is overexpressed on certain cancers, such as ovarian cancer, and a potent chemotherapy drug, vinblastine. It is being developed with a companion imaging agent, etarfolatide, that identifies patients that express the folate receptor and thus would likely respond to the treatment with<unk> . A Phase 3 study evaluating<unk>  for the treatment of platinum-resistant ovarian cancer (PROCEED trial) and a Phase 2b study(TARGET trial) in non-small-cell lung carcinoma (NSCLC) are ongoing.<unk>  is designed to deliver the toxic vinblastine drug selectively to cells expressing the folate receptor using folate targeting.
A Marketing Authorization Application (MAA) filing for<unk>  and etarfolatide for the treatment of patients with folate receptor-positive platinum-resistant ovarian cancer in combination with doxorubicin, pegylated liposomal doxorubicin (PLD), has been accepted by the European Medicines Agency. The drug received an orphan drug status in Europe in March 2012. Merck & Co. acquired the development and marketing rights to this experimental cancer drug from Endocyte in April 2012. The drug received orphan drug status in Europe in March 2012. Endocyte remains responsible for the development and commercialization of etarfolatide, a non-invasive companion imaging agent used to identify patients expressing the folate receptor that will likely respond to treatment with<unk> .<unk>  is designed to deliver the toxic vinblastine drug selectively to cells expressing the folate receptor using folate targeting.
Merck ($MRK) and partner Endocyte ($ECYT) have stopped a late-stage study of the ovarian cancer-treating<unk>  on the advice of a data safety monitoring board, saying the much-hyped drug failed to move the needle on progression-free survival.
Vintafolide
Quinagolide
Olaflur
Pergolide
Oxyphenisatine
Miglustat
Flunisolide 
Eliglustat